Nomogram model for predicting early recurrence for resectable pancreatic cancer: A multicenter study

Quan Man,Huifang Pang,Yuexiang Liang,Shaofei Chang,Junjin Wang,Song Gao
DOI: https://doi.org/10.1097/md.0000000000037440
IF: 1.6
2024-03-09
Medicine
Abstract:In 2022, approximately 62210 patients in the US will be newly diagnosed with pancreatic cancer, equating to approximately 170 new cases each day. [ 1 ] The incidence of pancreatic cancer is increasing at an annual rate of 0.5% to 1.0% and is projected to be the second leading cause of cancer-related deaths in the US by 2030. [ 2 ] Pancreatic ductal adenocarcinoma (PDAC) accounts for most (90%) pancreatic neoplasms and has a 5-year survival rate of < 11% [ 1 ] ; although it can be treated using surgical resection, only a small proportion of cases are detected at an early stage to allow this procedure. Moreover, even patients with resectable pancreatic cancer have unsatisfactory long-term outcomes, with a 5-year postoperative survival rate of just 20% to 30%, which is due to many of them relapsing even after curative resection, with a postoperative recurrence rate of 50% to 60%. [ 3 ] The poor outcomes could be mainly attributed to the presence of occult tumor spread (which contributes to distant metastasis) as early as at the time of diagnosis, the persistence of tumor cells around the resection area (which is responsible for local recurrence) after radical tumor resection, and the lack of effective systemic therapies. [ 4–6 ] Moreover, approximately 50% of patients experience recurrence within the first postoperative year, which is considered as early recurrence (ER). [ 7 ]
medicine, general & internal
What problem does this paper attempt to address?